Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform. They achieved a landmark approval for their hemophilia B gene therapy, marking a significant advancement in genomic medicine. Building on this success, uniQure is advancing clinical programs for Huntington’s disease and developing a pipeline of preclinical candidates. Orignally spunout as Amsterdam Molecular Therapeutics BV (AMT).
